



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/01/2019  
LAST REVIEW DATE: 11/19/2020  
LAST CRITERIA REVISION DATE: 11/19/2020  
ARCHIVE DATE:

---

## **MULTIPLE SCLEROSIS INJECTABLE THERAPY:**

**AVONEX® (interferon beta-1a)**  
**BETASERON® (interferon beta-1b)**  
**COPAXONE® (glatiramer acetate)**  
**EXTAVIA® (interferon beta-1b)**  
**GLATIRAMER (glatiramer acetate)**  
**GLATOPA® (glatiramer acetate)**  
**KESIMPTA® (ofatumumab)**  
**PLEGRIDY™ (peginterferon beta-1a)**  
**REBIF® (interferon beta-1a)**

---

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

**BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.**

---

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/01/2019  
LAST REVIEW DATE: 11/19/2020  
LAST CRITERIA REVISION DATE: 11/19/2020  
ARCHIVE DATE:

---

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

---

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com). **Incomplete forms or forms without the chart notes will be returned.**

---

## Interferons and Glatiramer

### Criteria:

- **Criteria for initial therapy:** Avonex, Betaseron, Copaxone, Extavia, glatiramer acetate, Glatopa, Plegridy, and Rebif is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
  1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Neurologist
  2. Individual is 18 years of age or older
  3. A confirmed diagnosis of **ONE** of the following:
    - a. Individual has a relapsing form of multiple sclerosis, **EITHER** of the following:
      - i. Relapsing-remitting MS (RRMS)
      - ii. Secondary progressive MS (SPMS)
      - iii. Progressive-Relapsing MS (PRMS)
    - b. Individual has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
  4. There are **NO** contraindications
  5. Requested treatment is not to be used concurrently with other injectable MS agent or oral MS medications (e.g., Aubagio (teriflunomide), Gilenya (fingolimod), Mayzent (siponimod) Tecfidera (dimethyl fumarate), etc., except for Ampyra (dalfampridine), which is intended to improve walking speed rather than disease progression)
  6. For **glatiramer acetate** and **Glatopa** only: Individual has failure (a trial of at least 4 weeks), contraindication or intolerance to brand Copaxone

**Initial approval duration:** 6 months

---

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

---

**Criteria for continuation of coverage (renewal request):** Avonex, Betaseron, Copaxone, Extavia, glatiramer acetate, Glatopa, Plegridy, and Rebif is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Neurologist
2. Individual's condition responded while on therapy
  - a. Response is defined as achieves and maintains **THREE** of the following:
    - i. Mild/minimal to no functional neurologic (pyramidal, cerebellar, brainstem, sensory) disabilities
    - ii. Ambulatory without need for assistance
    - iii. Reduction in number of exacerbations or relapses of MS
    - iv. Prolonged time to exacerbation or relapses of MS
    - v. Reduction in hospitalizations for MS
    - vi. There is no evidence of disease progression
3. Individual has been adherent with the medication
4. Individual has not developed any contraindications or other significant unacceptable adverse drug effects that may exclude continued use
5. There are no significant interacting drugs
6. Requested treatment is not to be used concurrently with other MS injectable or oral MS medications (e.g., Aubagio (teriflunomide), Gilenya (fingolimod), Mayzent (siponimod), Tecfidera (dimethyl fumarate), etc., except for Ampyra (dalfampridine), which is intended to improve walking speed rather than disease progression)

**Renewal duration:** 12 months

---

## Kesimpta (ofatumumab)

**Criteria:**

- **Criteria for initial therapy:** Kesimpta (ofatumumab) is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Neurologist
  2. Individual is 18 years of age or older
  3. A confirmed diagnosis of **ONE** of the following:
    - a. Individual has a relapsing form of multiple sclerosis, **EITHER** of the following:
      - i. Relapsing-remitting MS (RRMS)

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/01/2019  
LAST REVIEW DATE: 11/19/2020  
LAST CRITERIA REVISION DATE: 11/19/2020  
ARCHIVE DATE:

---

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

---

- ii. Secondary progressive MS (SPMS)
    - iii. Progressive-Relapsing MS (PRMS)
  - b. Individual has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
4. Individual has **ONE** of the following:
  - a. Had at least one relapse in the previous year
  - b. Had two relapses in the previous 2 years
  - c. There is a T1 gadolinium-enhancing (GdE) lesion in the previous year
5. Individual has an Expanded Disability Status Scale (EDDS) score of less than or equal to 5.5
6. Has a failed response to two or more drugs indicated for the treatment of relapsing forms of multiple sclerosis (such as Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), Gilenya (fingolimod), Copaxone (glatiramer), or interferons such as, Rebif, Betaseron, Intron A, Intron B)
7. There is evidence of testing for quantitative serum immunoglobulins prior to initiation of therapy
8. There is evidence of testing for hepatitis B infection prior to initiation of therapy
9. There is evidence that the individual does not have an active infection with hepatitis B virus
10. Requested treatment is not to be used concurrently with other injectable MS agent or oral MS medications (e.g., Aubagio (teriflunomide), Gilenya (fingolimod), Mayzent (siponimod) Tecfidera (dimethyl fumarate), etc., except for Ampyra (dalfampridine), which is intended to improve walking speed rather than disease progression)

**Initial approval duration:** 6 months

**Criteria for continuation of coverage (renewal request):** Kesimpta (ofatumumab) is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met:

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Neurologist
2. Individual's condition responded while on therapy
  - a. Response is defined as achieves and maintains **THREE** of the following:
    - i. Mild/minimal to no functional neurologic (pyramidal, cerebellar, brainstem, sensory) disabilities
    - ii. Ambulatory without need for assistance
    - iii. Reduction in number of exacerbations or relapses of MS
    - iv. Prolonged time to exacerbation or relapses of MS
    - v. Reduction in hospitalizations for MS
    - vi. There is no evidence of disease progression



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/01/2019  
LAST REVIEW DATE: 11/19/2020  
LAST CRITERIA REVISION DATE: 11/19/2020  
ARCHIVE DATE:

---

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

---

3. Individual has been adherent with the medication
4. Individual has not developed any contraindications or other significant unacceptable adverse drug effects that may exclude continued use
5. There are no significant interacting drugs
6. Requested treatment is not to be used concurrently with other MS injectable or oral MS medications (e.g., Aubagio (teriflunomide), Gilenya (fingolimod), Mayzent (siponimod), Tecfidera (dimethyl fumarate), etc., except for Ampyra (dalfampridine), which is intended to improve walking speed rather than disease progression)

**Renewal duration:** 12 months

- Avonex, Betaseron, Copaxone, Extavia, glatiramer acetate, Glatopa, Kesimpta, Plegridy, and Rebif for all other indications not previously listed is considered **experimental or investigational** and will not be covered when any one or more of the following criteria are met:
1. Lack of final approval from the Food and Drug Administration;
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes;
  3. Insufficient evidence to support improvement of the net health outcome;
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; **or**
  5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, but are not limited to:

- Treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration.

---

### **Description:**

Multiple sclerosis (MS) is an unpredictable and potentially disabling disease of the central nervous system, which interrupts the flow of information within the brain, and between the brain and body. The disease is thought to be triggered in a genetically susceptible individual by a combination of one or more environmental factors. In MS, the immune system attacks tissue and cells within the central nervous system (CNS) and causes damage to nerve connections resulting in neurological symptoms. Although MS is not curable, there is much an individual can do to manage the disease and symptoms it can cause. A number of medications have been shown to modify or slow the course of MS.

Because MS can affect any area of the brain, optic nerve, or spinal cord, MS can cause almost any neurologic symptom. Patients typically present as young adults with 2 or more clinically distinct episodes of CNS dysfunction with at least partial resolution. Typical episodes involve numbness, weakness, or dyscoordination affecting an arm, a leg, or both. Additional symptoms include pain, vertigo, cognitive deficits (e.g., impaired memory, attention,



An Independent Licensee of the Blue Cross Blue Shield Association

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 4/01/2019**  
**LAST REVIEW DATE: 11/19/2020**  
**LAST CRITERIA REVISION DATE: 11/19/2020**  
**ARCHIVE DATE:**

---

## **MULTIPLE SCLEROSIS INJECTABLE THERAPY**

---

or judgment), fatigue, speech deficits (e.g., dysarthria or less commonly aphasia), and bowel, bladder, and sexual dysfunction.

The pathological hallmark of MS is the cerebral or spinal plaque seen on magnetic resonance imaging (MRI). Plaques are discrete regions of demyelination with relative preservation of axons. However, the basis of the diagnosis remains the neurologic history and physical examination. Original diagnostic criteria required symptoms and signs disseminated in time and space (i.e., more than one episode involving more than one area of the CNS). These criteria have been largely replaced by the McDonald criteria, developed in 2001 by the International Panel on the Diagnosis of Multiple Sclerosis. The McDonald criteria retain many features of the original diagnostic criteria and are intended for use in both clinical practice and clinical trial settings. Diagnoses of “definite MS,” “possible MS,” or, if there is a better explanation for the clinical presentation, “not MS” are determined by findings on clinical exam, MRI, cerebrospinal fluid, and visual evoked potentials. The term “clinically isolated syndrome” (CIS) describes patients who have suffered a first clinical attack but do not meet diagnostic criteria for definite MS. The McDonald criteria were updated in 2010 and allows the diagnosis of MS in some patients with CIS.

There are four recognized clinical forms of MS: relapsing remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). RRMS is the most common form of the disease. As the understanding of the disease process in MS advances, the definitions have evolved:

---

### **Definitions:**

#### **National Multiple Sclerosis Society 1996 Disease-Course Definitions:**

- **Primary Progressive (PPMS):**  
PPMS is characterized by steady worsening of neurologic functioning, without any distinct relapses (also called attacks or exacerbations) or periods of remission. Rate of progression may vary over time with occasional plateaus or temporary improvement but the progression is continuous.
- **Progressive-Relapsing (PRMS):**  
PRMS is the least common of the four disease courses. Similar to PPMS, individuals with PRMS experience steadily worsening neurologic function and disease progression from the very beginning, in addition to occasional relapses like those experienced with RRMS. Because PRMS is progressive from onset, it may be initially diagnosed as PPMS, and then subsequently changed to PRMS when a relapse occurs. Although this disease course is progressive from the outset, each individual’s symptoms and rate of progression will be different.
- **Relapsing-Remitting (RRMS):**  
RRMS is characterized by clearly defined attacks of worsening neurologic function. These attacks, often called relapses, flare-ups or exacerbations, are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely and there is no apparent progression of disease. RRMS is the most common disease course at the time of diagnosis. Approximately 85 percent of individuals are initially diagnosed with RRMS, compared to 10-15 percent with progressive forms of the disease.
- **Secondary Progressive (SPMS):**  
SPMS follows after the relapsing-remitting disease course (RRMS). Of the 85 percent of individuals who are initially diagnosed with RRMS, most will eventually transition to SPMS, which means that after a period of



An Independent Licensee of the Blue Cross Blue Shield Association

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 4/01/2019**  
**LAST REVIEW DATE: 11/19/2020**  
**LAST CRITERIA REVISION DATE: 11/19/2020**  
**ARCHIVE DATE:**

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

time in which they experience relapses and remissions, the disease will begin to progress more steadily (although not necessarily more quickly), with or without any relapses (also called attacks or exacerbations).

### National Multiple Sclerosis Society 2013 Disease-Course Revisions:

- **Clinically Isolated Syndrome (CIS):**  
 CIS is a first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system. The episode, which by definition must last for at least 24 hours, is characteristic of multiple sclerosis but does not yet meet the criteria for a diagnosis of MS because people who experience a CIS may or may not go on to develop MS.
- **Relapsing-Remitting (RRMS):**  
 RRMS is characterized by clearly defined attacks of new or worsening neurologic function. These attacks, often called relapses, flare-ups or exacerbations, are followed by partial or complete recovery periods (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission. Approximately 85 percent of people with MS are initially diagnosed with RRMS.
- **Primary Progressive (PPMS):**  
 PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions. Approximately 15 percent of people with MS are diagnosed with PPMS.
- **Secondary Progressive (SPMS):**  
 SPMS follows after the relapsing-remitting disease course (RRMS). Most individuals who are diagnosed with RRMS will eventually transition to a secondary progressive course in which there is a progressive worsening of neurologic function (accumulation of disability) over time.

### **McDonald criteria:**

<b>Clinical Presentation</b>	<b>Additional Data Needed</b>
* 2 or more attacks (relapses) * 2 or more objective clinical lesions	None; clinical evidence will suffice (additional evidence desirable but must be consistent with MS)
* 2 or more attacks * 1 objective clinical lesion	Dissemination in space, demonstrated by: * MRI * <b>or</b> a positive CSF and 2 or more MRI lesions consistent with MS * <b>or</b> further clinical attack involving different site
* 1 attack * 2 or more objective clinical lesions	Dissemination in time, demonstrated by: * MRI * <b>or</b> second clinical attack
* 1 attack * 1 objective clinical lesion (monosymptomatic presentation)	Dissemination in space demonstrated by: * MRI * <b>or</b> positive CSF and 2 or more MRI lesions consistent with MS <b>and</b> Dissemination in time demonstrated by: * MRI * <b>or</b> second clinical attack



An Independent Licensee of the Blue Cross Blue Shield Association

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 4/01/2019**  
**LAST REVIEW DATE: 11/19/2020**  
**LAST CRITERIA REVISION DATE: 11/19/2020**  
**ARCHIVE DATE:**

## MULTIPLE SCLEROSIS INJECTABLE THERAPY

Insidious neurological progression suggestive of MS (primary progressive MS)	One year of disease progression (retrospectively or prospectively determined) <b>and</b> Two of the following: a. Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive VEP) b. Positive spinal cord MRI (two focal T2 lesions) c. Positive CSF
--	--

### Kurtzke Expanded Disability Status Scale (EDSS):

A method of quantifying disability in MS.

The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are:

- Pyramidal
- Cerebellar
- Brainstem
- Sensory
- Bowel and bladder
- Visual
- Cerebral
- Other

EDSS steps of 1.0-4.5 refer to people with MS who are fully ambulatory. EDSS steps of 5.0-9.5 are defined by the impairment to ambulation.

<b>Kurtzke Expanded Disability Status Scale</b>	
0.0	Normal neurological examination
1.0	No disability, minimal signs in one FS
1.5	No disability, minimal signs in more than one FS
2.0	Minimal disability in one FS
2.5	Mild disability in one FS or minimal disability in two FS
3.0	Moderate disability in one FS, or mild disability in three or four FS. Fully ambulatory
3.5	Fully ambulatory but with moderate disability in one FS and more than minimal disability in several others
4.0	Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe disability; able to walk without aid or rest some 500 meters
4.5	Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance; characterized by relatively severe disability; able to walk without aid or rest some 300 meters.
5.0	Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily activities (work a full day without special provisions)



## MULTIPLE SCLEROSIS INJECTABLE THERAPY

5.5	Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude full daily activities
6.0	Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 meters with or without resting
6.5	Constant bilateral assistance (canes, crutches, braces) required to walk about 20 meters without resting
7.0	Unable to walk beyond approximately five meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day
7.5	Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot carry on in standard wheelchair a full day; May require motorized wheelchair
8.0	Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; retains many self-care functions; generally has effective use of arms
8.5	Essentially restricted to bed much of day; has some effective use of arms retains some self-care functions
9.0	Confined to bed; can still communicate and eat.
9.5	Totally helpless bed patient; unable to communicate effectively or eat/swallow
10.0	Death due to MS

### **Resources:**

Avonex (interferon beta-1a) product information, revised by manufacturer Biogen Inc 03-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Betaseron (interferon beta-1b) product information, revised by manufacturer Bayer HealthCare Pharmaceuticals Inc 10-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Copaxone (glatiramer acetate) product information, revised by manufacturer Teva Neuroscience Inc 07-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Extavia (interferon beta-1b) product information, revised by manufacturer Novartis Pharmaceuticals Corporation 06-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Glatiramer acetate product information, revised by manufacturer Mylan Pharmaceuticals Inc 02-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Glatopa (glatiramer acetate) product information, revised by manufacturer Sandoz Inc 01-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Kesimpta (ofatumumab) product information, revised by manufacturer Novartis Pharmaceuticals Corporation 08-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Plegridy (peginterferon beta-1a) product information, revised by manufacturer Biogen Inc 03-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.



An Independent Licensee of the Blue Cross Blue Shield Association

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 4/01/2019**  
**LAST REVIEW DATE: 11/19/2020**  
**LAST CRITERIA REVISION DATE: 11/19/2020**  
**ARCHIVE DATE:**

---

## **MULTIPLE SCLEROSIS INJECTABLE THERAPY**

---

Rebif (interferon beta-1a) product information, revised by manufacturer EMD Serono Inc 06-2020, at DailyMed <http://dailymed.nlm.nih.gov> accessed October 8, 2020.

Olek MJ, Mowry E. Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults. In: UpToDate, Gonzalez-Scarano F, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Accessed on October 9, 2020.

Olek MJ, Howard J. Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis. In: UpToDate, Gonzalez-Scarano F, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Accessed on October 9, 2020.

---